Pain, PostoperativeLASTENCT03296189
Local Anaesthetic and Steroid in the Ureter
A study testing Levobupivacaine and Dexamethasone Sodium Phosphate in people with Pain, Postoperative and Ureter Stone, run by The Adelaide and Meath Hospital, incorporating The National Children's Hospital at 1 site in Ireland.
Trial summary
Précis: Randomised control trial to evaluate safety and efficacy of intraluminal injection of high pH-high concentration of a long-acting local anesthetic and long-acting glucocorticoid in the ureter after ureteroscopy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pain, Postoperative, Ureter Stone
- What is being tested?
- Levobupivacaine and Dexamethasone Sodium Phosphate
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 1 siteIreland
- Study dates
- 1 Nov 2018to 31 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Any patient undergoing ureteroscopy for ureteric stone disease
- Able to undergo a general anaesthetic
- At least 18 years old
- Willing and able to complete patient symptom questionnaires
Who cannot join
- Solitary Kidney
- Renal failure
- Anatomic bladder or ureteral abnormality
- Uncorrected coagulopathy
- Previous cystectomy or urinary diversion
- Neurogenic bladder
Show all 19Show fewer
- Interstitial cystitis
- Transplanted kidney
- Pregnancy
- Requires an indwelling catheter
- Recurrent urinary tract infections
- Pelvic kidney
- Requires bilateral treatment/stents
- Previous bladder or ureteral reconstructive surgery
- Ureteral perforation during procedure
- Known sensitivity to lidocaine
- Febrile at time of randomization or treatment
- Requires spinal anaesthetic
- Stenting without stone treatment
Trial locations and contacts
1 site in 1 country.
Rustom Manecksha contact
Ireland1 site
Adelaide and Meath incorporating National Children's hopsital
Dublin, 24
Nikita R Bhatt, 00353860609430, nikitarb89@gmail.com
Rustom P Manecksha, rustom.manecksha@gmail.com
About this study
Official title: Intraluminal Ureteric Injection of High Concentration Alkalinised Long-acting Local Anaesthetic and STeroid Post urEteroscopy: A Prospective Double Blinded Randomised Controlled Trial (LASTE Trial)
Précis:
Randomised control trial to evaluate safety and efficacy of intraluminal injection of high pH-high concentration of a long-acting local anesthetic and long-acting glucocorticoid in the ureter after ureteroscopy.
Read more
Objectives:
To evaluate a novel method to ameliorate post-ureteroscopy pain in all patients (with and without stents)
Endpoints:
Primary endpoint: mean visual analog pain scale (VAS) post-operatively starting at 1 hour, 4 hours, 8 hours, 24 hours and 7 days post-procedure (minimum of 3 VAS scores). VAS pain, ureteral stent symptoms and analgesic requirement will be assessed at different points during this time period.
Secondary endpoint: Postoperative Nausea/Vomiting (PONV), safety of intraluminal injection of high concentration alkalinized local anaesthetic solution by comparing adverse events between placebo and treatment arms. In addition, rehospitalisation rates and postoperative length of stay will be compared between the three groups.
Population:
150 adult patients undergoing ureteroscopy for ureteric stone disease stratified into negative ureteroscopy and those treated for a stone with or without stent insertion postoperatively Number of Sites: Tallaght Hospital Study Duration: 8 months
Read the detailed description
Study Rationale Ureteroscopy is a widely performed procedure in urology. Pain is one of the commonest complications after ureteroscopy and one of the common reasons for re-admission after this procedure. Insertion of a stent post-ureteroscopy can cause pain affecting daily activities in 80% of the patients. Pain post ureteroscopy is multi-factorial and currently there is no specific method used clinically to treat this. Intraluminal injection of local anesthetic solution in the ureter has been extensively studied in the animal model with positive results. Intraluminal injection steroids has also been studied previously and steroids have also been used in medical expulsive therapy for ureteric stones previously. The investigators are proposing the use of high concentration alkalinized long-acting local anaesthetic levo-bupivicaine and long-acting steroid dexamethasone for post-ureteroscopy pain. It is simple, cheap, safe, easy to perform and widely available.
Background Intraluminal injection of local anesthetics (LA) in the ureter has been studied previously in animal models. Burdgya et al in 1986, USSR examined effects of LA on guinea pig ureters . Action potential of ureteric smooth muscle has initial fast component consisting of repeated gradually decaying spikes and a subsequent slow component i.e plateau. This action potential is accompanied by a brief contraction. Two opposite effects of LA occur on ureteric smooth muscle: Low concentrations of procaine, lignocaine and tetracaine (0.1-1 mM) at pH 7.4 increased duration of slow plateau of the evoked action potentials. At higher concentrations lignocaine (5mM) and tetracaine (0.5mM) caused complete inhibition of evoked action potentials and phasic contractions. Procaine 5mM predominantly inhibited contractile responses. High pH (9) significantly increased while low pH (pH 6) decreased the inhibitory action of procaine and lignocaine. Tetracaine had the most potent inhibitory action on ureter smooth muscle with the weakest stimulant action while lignocaine had stronger inhibitory effect on ureter smooth muscle than procaine. Ross et al in 1972 reported intraluminal injection of 2% lignocaine reduced peristaltic activity in 5 out of 15 ureters in their patients with no effect in the remaining group.
Andersson and Ulmsten found that local instillation of 4% lignocaine in their patients caused an initial brief stimulation followed by reduced activity. Tsuchida in 197 studied dog ureters to report prompt inhibitory effect of 4% lignocaine applied to mucosa invivo with no effect when applied to adventitia.
Struthers in 1976 in his invivo dog studies found both systemic and intraluminal administration of lignocaine, procaine and mepivacaine caused only hyperperistalsis and never inhibition. Sur et al published a study with intravesical injection of ropivacaine before ureteroscopic surgery demonstrated trends toward decreased pain and voiding symptoms. Patients received five injections of 2 mL 0.5% ropivacaine around the ureteral orifice or to the control cohort, who received five injections of 2 mL of 0.9% normal saline in identical locations. A pilot study suggested that PSD597 (intravesical alkalinized lidocaine) is effective for treating interstitial cystitis/painful bladder syndrome (IC/PBlS) , providing short-term amelioration of symptoms in a substantial proportion of patients, with a strong suggestion that repeating the treatment has a potentially cumulative effect. A randomized controlled trial comparing injection of non-irritating salt water (placebo), and half an injection of pH buffered lidocaine before the stent placement in patients undergoing ureteroscopy is currently being conducted. Till date there is no human study assessing the efficacy and safety of high concentration alkalinised long-acting LA injection for post-ureteroscopy pain based on the results of the animal studies outlined above.
The anaesthetic drug chosen for this study is levobupivacaine (Chirocaine™ -): it is S-isomer of bupivacaine, an amino-amide local anaesthetic widely used in regional anaesthesia, in postoperative analgesia and in treatment of acute and chronic pain. This drug produces sensory and motor nerve conduction block, acting on sodium channels of the cell membrane - sensitive to electric stimulus - but also on potassium and calcium channels. Moreover, it is remarkable for a rapid onset time and a long duration. In vitro and in vivo pharmacodynamic studies show that levobupivacaine has the same potency as bupivacaine, though the former is less likely to cause cardio- and neurotoxicity.
The effect of steroids on ureteric motility has previously been studied in in-vitro sheep models. Glucocorticoids inhibit the release of phospholipase A2 enzyme which catalyses the release of arachidonic acid from membrane phospholipids and thereby can have a spasmolytic action on the ureter by a prostaglandin-inhibitory action. Dexamethasone has shown the most potent dose dependant effect on the ureteral motility, it blocks ureteral motility in high concentrations within 24 minutes of instillation. Being a long-acting steroid, its duration of action in previous studies on nerve blocks and intra-articular injections is demonstrated at 12 weeks.
Study population: 150 patients undergoing ureteroscopy for ureteric stones:
- Ureteric stone treatment (including proximal, mid and distal ureteric stones) with or without JJ stent insertion OR
- Negative ureteroscopy (no stone found)
Pre and intraop: Obtain informed written consent pre-operatively with a pre-operative pain score, and rule out any allergies. Standardised uniform anesthetic regimen in all ureteroscopies.Post-ureteroscopy: drain the renal pelvis
- Conditions
- Pain, Postoperative, Ureter Stone
- Being tested
- Levobupivacaine, Dexamethasone Sodium Phosphate, Placebos
- Keywords
- ureteroscopy, ureteric stent, intraluminal, local anaesthetic/anesthetic, steroid/glucocorticoid
- Medical subject headings
- Pain, Postoperative, Ureterolithiasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LevobupivacaineDrug
intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
Dexamethasone Sodium PhosphateDrug
intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
PlacebosDrug
10 mls normal saline
| Study group | Role | What they receive |
|---|---|---|
| Local anaesthetic | Active comparator | Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis Receives: Drug: Levobupivacaine |
| Local anaesthetic + steroid | Active comparator | Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis Receives: Drug: Dexamethasone Sodium Phosphate |
| Placebo | Placebo comparator | Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis Receives: Drug: Placebos |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain
Visual Analog Pain Scale (VAS) at least 3 different time points post-ureteroscopy
Measured: at up to 7 days post op
Secondary outcomes (4)
Postoperative Nausea and Vomiting (PONV)
Measured: at up to 7 days post op
Length of stay post-op
Measured: at up to 7 days post op
rehospitalisation rate
Measured: at up to 7 days post op
Need for analgesia
Measured: at up to 7 days post op
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2017
- Study start1 Nov 2018 (estimated)
- Primary completion1 Dec 2019 (estimated)
- Study completion31 Dec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Pain, PostoperativeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Three arm double-blinded prospective randomised controlled trial
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Adelaide and Meath Hospital, incorporating The National Children's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rustom P Manecksha, MD, FRCS (Urol.), The Adelaide and Meath Hospital, incorporating The National Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03296189
- Sponsor's protocol ID
- AMNCH-GU-2017-2
- Acronym
- LASTE
- Status last verified
- Jan 2018
- First submitted
- 8 Sep 2017
- Last updated
- 17 Jan 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
El Harrech Y, Abakka N, El Anzaoui J, Ghoundale O, Touiti D. Ureteral stenting after uncomplicated ureteroscopy for distal ureteral stones: a randomized, controlled trial. Minim Invasive Surg. 2014;2014:892890. doi: 10.1155/2014/892890. Epub 2014 Nov 9.
PubMed 25431663Burdyga ThV, Magura IS. The effects of local anaesthetics on the electrical and mechanical activity of the guinea-pig ureter. Br J Pharmacol. 1986 Jul;88(3):523-30. doi: 10.1111/j.1476-5381.1986.tb10232.x.
PubMed 3742148Ross JA EP, Kirkland IS. Ibid. 1972:125.
Andersson KE, Ulmsten U. Effects of spinal anaesthesia, lidocaine, and morphine, on the motility of the human ureter in vivo. Scand J Urol Nephrol. 1975;9(3):236-42. doi: 10.3109/00365597509134219.
PubMed 1209180Boyarsky ASaS. The Pharmacology of the Urinary Tract. In: Caine M, editor.1984.
Sur RL, Haleblian GE, Cantor DA, Springhart WP, Albala DM, Preminger GM. Efficacy of intravesical ropivacaine injection on urinary symptoms following ureteral stenting: a randomized, controlled study. J Endourol. 2008 Mar;22(3):473-8. doi: 10.1089/end.2007.9847.
PubMed 18290733Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009 Apr;103(7):910-8. doi: 10.1111/j.1464-410X.2008.08162.x. Epub 2008 Nov 13.
PubMed 19021619The American Heritage® Stedman's Medical Dictionary. http://www.dictionary.com/browse/life-expectancy. Accessed 13/12/16. 2002.
Angelo-Khattar M, Thulesius O, Cherian T. The effect of glucocorticosteroids on in vitro motility of the ureter of the sheep. Br J Pharmacol. 1989 Mar;96(3):527-30. doi: 10.1111/j.1476-5381.1989.tb11849.x.
PubMed 2720291Manchikanti L, Manchikanti KN, Manchukonda R, Cash KA, Damron KS, Pampati V, McManus CD. Evaluation of lumbar facet joint nerve blocks in the management of chronic low back pain: preliminary report of a randomized, double-blind controlled trial: clinical trial NCT00355914. Pain Physician. 2007 May;10(3):425-40.
PubMed 17525777
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intraluminal Ureteric Injection of High Concentration Alkalinised Long-acting Local Anaesthetic and STeroid Post urEteroscopy: A Prospective Double Blinded Randomised Controlled Trial (LASTE Trial)
- ClinicalTrials.gov ID
- NCT03296189
- Acronym / sponsor ID
- LASTE / AMNCH-GU-2017-2
- Conditions
- Pain, Postoperative, Ureter Stone
- Keywords
- ureteroscopy, ureteric stent, intraluminal, local anaesthetic/anesthetic, steroid/glucocorticoid
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- The Adelaide and Meath Hospital, incorporating The National Children's HospitalUniversity, hospital or other
- Study start
- 1 Nov 2018 (estimated)
- Primary completion
- 1 Dec 2019 (estimated)
- Study completion
- 31 Dec 2019 (estimated)
- First posted
- 28 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Précis:
Randomised control trial to evaluate safety and efficacy of intraluminal injection of high pH-high concentration of a long-acting local anesthetic and long-acting glucocorticoid in the ureter after ureteroscopy.
Objectives:
To evaluate a novel method to ameliorate post-ureteroscopy pain in all patients (with and without stents)
Endpoints:
Primary endpoint: mean visual analog pain scale (VAS) post-operatively starting at 1 hour, 4 hours, 8 hours, 24 hours and 7 days post-procedure (minimum of 3 VAS scores). VAS pain, ureteral stent symptoms and analgesic requirement will be assessed at different points during this time period.
Secondary endpoint: Postoperative Nausea/Vomiting (PONV), safety of intraluminal injection of high concentration alkalinized local anaesthetic solution by comparing adverse events between placebo and treatment arms. In addition, rehospitalisation rates and postoperative length of stay will be compared between the three groups.
Population:
150 adult patients undergoing ureteroscopy for ureteric stone disease stratified into negative ureteroscopy and those treated for a stone with or without stent insertion postoperatively Number of Sites: Tallaght Hospital Study Duration: 8 months
Detailed description
Study Rationale Ureteroscopy is a widely performed procedure in urology. Pain is one of the commonest complications after ureteroscopy and one of the common reasons for re-admission after this procedure. Insertion of a stent post-ureteroscopy can cause pain affecting daily activities in 80% of the patients. Pain post ureteroscopy is multi-factorial and currently there is no specific method used clinically to treat this. Intraluminal injection of local anesthetic solution in the ureter has been extensively studied in the animal model with positive results. Intraluminal injection steroids has also been studied previously and steroids have also been used in medical expulsive therapy for ureteric stones previously. The investigators are proposing the use of high concentration alkalinized long-acting local anaesthetic levo-bupivicaine and long-acting steroid dexamethasone for post-ureteroscopy pain. It is simple, cheap, safe, easy to perform and widely available.
Background Intraluminal injection of local anesthetics (LA) in the ureter has been studied previously in animal models. Burdgya et al in 1986, USSR examined effects of LA on guinea pig ureters . Action potential of ureteric smooth muscle has initial fast component consisting of repeated gradually decaying spikes and a subsequent slow component i.e plateau. This action potential is accompanied by a brief contraction. Two opposite effects of LA occur on ureteric smooth muscle: Low concentrations of procaine, lignocaine and tetracaine (0.1-1 mM) at pH 7.4 increased duration of slow plateau of the evoked action potentials. At higher concentrations lignocaine (5mM) and tetracaine (0.5mM) caused complete inhibition of evoked action potentials and phasic contractions. Procaine 5mM predominantly inhibited contractile responses. High pH (9) significantly increased while low pH (pH 6) decreased the inhibitory action of procaine and lignocaine. Tetracaine had the most potent inhibitory action on ureter smooth muscle with the weakest stimulant action while lignocaine had stronger inhibitory effect on ureter smooth muscle than procaine. Ross et al in 1972 reported intraluminal injection of 2% lignocaine reduced peristaltic activity in 5 out of 15 ureters in their patients with no effect in the remaining group.
Andersson and Ulmsten found that local instillation of 4% lignocaine in their patients caused an initial brief stimulation followed by reduced activity. Tsuchida in 197 studied dog ureters to report prompt inhibitory effect of 4% lignocaine applied to mucosa invivo with no effect when applied to adventitia.
Struthers in 1976 in his invivo dog studies found both systemic and intraluminal administration of lignocaine, procaine and mepivacaine caused only hyperperistalsis and never inhibition. Sur et al published a study with intravesical injection of ropivacaine before ureteroscopic surgery demonstrated trends toward decreased pain and voiding symptoms. Patients received five injections of 2 mL 0.5% ropivacaine around the ureteral orifice or to the control cohort, who received five injections of 2 mL of 0.9% normal saline in identical locations. A pilot study suggested that PSD597 (intravesical alkalinized lidocaine) is effective for treating interstitial cystitis/painful bladder syndrome (IC/PBlS) , providing short-term amelioration of symptoms in a substantial proportion of patients, with a strong suggestion that repeating the treatment has a potentially cumulative effect. A randomized controlled trial comparing injection of non-irritating salt water (placebo), and half an injection of pH buffered lidocaine before the stent placement in patients undergoing ureteroscopy is currently being conducted. Till date there is no human study assessing the efficacy and safety of high concentration alkalinised long-acting LA injection for post-ureteroscopy pain based on the results of the animal studies outlined above.
The anaesthetic drug chosen for this study is levobupivacaine (Chirocaine™ -): it is S-isomer of bupivacaine, an amino-amide local anaesthetic widely used in regional anaesthesia, in postoperative analgesia and in treatment of acute and chronic pain. This drug produces sensory and motor nerve conduction block, acting on sodium channels of the cell membrane - sensitive to electric stimulus - but also on potassium and calcium channels. Moreover, it is remarkable for a rapid onset time and a long duration. In vitro and in vivo pharmacodynamic studies show that levobupivacaine has the same potency as bupivacaine, though the former is less likely to cause cardio- and neurotoxicity.
The effect of steroids on ureteric motility has previously been studied in in-vitro sheep models. Glucocorticoids inhibit the release of phospholipase A2 enzyme which catalyses the release of arachidonic acid from membrane phospholipids and thereby can have a spasmolytic action on the ureter by a prostaglandin-inhibitory action. Dexamethasone has shown the most potent dose dependant effect on the ureteral motility, it blocks ureteral motility in high concentrations within 24 minutes of instillation. Being a long-acting steroid, its duration of action in previous studies on nerve blocks and intra-articular injections is demonstrated at 12 weeks.
Study population: 150 patients undergoing ureteroscopy for ureteric stones:
- Ureteric stone treatment (including proximal, mid and distal ureteric stones) with or without JJ stent insertion OR
- Negative ureteroscopy (no stone found)
Pre and intraop: Obtain informed written consent pre-operatively with a pre-operative pain score, and rule out any allergies. Standardised uniform anesthetic regimen in all ureteroscopies.Post-ureteroscopy: drain the renal pelvis
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
- Model description
- Three arm double-blinded prospective randomised controlled trial
| Arm | Type | Receives |
|---|---|---|
| Local anaesthetic | Active comparator | Drug: LevobupivacainePost-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis |
| Local anaesthetic + steroid | Active comparator | Drug: Dexamethasone Sodium PhosphatePost-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis |
| Placebo | Placebo comparator | Drug: PlacebosPost-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Any patient undergoing ureteroscopy for ureteric stone disease
- Able to undergo a general anaesthetic
- At least 18 years old
- Willing and able to complete patient symptom questionnaires
Key exclusion criteria (19 listed)
- Solitary Kidney
- Renal failure
- Anatomic bladder or ureteral abnormality
- Uncorrected coagulopathy
- Previous cystectomy or urinary diversion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Levobupivacaineintraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls | Drug | Local anaesthetic |
| Dexamethasone Sodium Phosphateintraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone | Drug | Local anaesthetic + steroid |
| Placebos10 mls normal saline | Drug | Placebo |
Primary outcome
Pain
Time frame: at up to 7 days post op
Visual Analog Pain Scale (VAS) at least 3 different time points post-ureteroscopy
4 secondary outcomes
Postoperative Nausea and Vomiting (PONV)
Time frame: at up to 7 days post op
Length of stay post-op
Time frame: at up to 7 days post op
rehospitalisation rate
Time frame: at up to 7 days post op
Need for analgesia
Time frame: at up to 7 days post op
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2018.
- Background: PubMed 25431663El Harrech Y, Abakka N, El Anzaoui J, Ghoundale O, Touiti D. Ureteral stenting after uncomplicated ureteroscopy for distal ureteral stones: a randomized, controlled trial. Minim Invasive Surg. 2014;2014:892890. doi: 10.1155/2014/892890. Epub 2014 Nov 9.
- Background: PubMed 3742148Burdyga ThV, Magura IS. The effects of local anaesthetics on the electrical and mechanical activity of the guinea-pig ureter. Br J Pharmacol. 1986 Jul;88(3):523-30. doi: 10.1111/j.1476-5381.1986.tb10232.x.
- BackgroundRoss JA EP, Kirkland IS. Ibid. 1972:125.
- Background: PubMed 1209180Andersson KE, Ulmsten U. Effects of spinal anaesthesia, lidocaine, and morphine, on the motility of the human ureter in vivo. Scand J Urol Nephrol. 1975;9(3):236-42. doi: 10.3109/00365597509134219.
- BackgroundBoyarsky ASaS. The Pharmacology of the Urinary Tract. In: Caine M, editor.1984.
- Background: PubMed 18290733Sur RL, Haleblian GE, Cantor DA, Springhart WP, Albala DM, Preminger GM. Efficacy of intravesical ropivacaine injection on urinary symptoms following ureteral stenting: a randomized, controlled study. J Endourol. 2008 Mar;22(3):473-8. doi: 10.1089/end.2007.9847.
- Background: PubMed 19021619Nickel JC, Moldwin R, Lee S, Davis EL, Henry RA, Wyllie MG. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009 Apr;103(7):910-8. doi: 10.1111/j.1464-410X.2008.08162.x. Epub 2008 Nov 13.
- BackgroundThe American Heritage® Stedman's Medical Dictionary. http://www.dictionary.com/browse/life-expectancy. Accessed 13/12/16. 2002.
- Background: PubMed 2720291Angelo-Khattar M, Thulesius O, Cherian T. The effect of glucocorticosteroids on in vitro motility of the ureter of the sheep. Br J Pharmacol. 1989 Mar;96(3):527-30. doi: 10.1111/j.1476-5381.1989.tb11849.x.
- Background: PubMed 17525777Manchikanti L, Manchikanti KN, Manchukonda R, Cash KA, Damron KS, Pampati V, McManus CD. Evaluation of lumbar facet joint nerve blocks in the management of chronic low back pain: preliminary report of a randomized, double-blind controlled trial: clinical trial NCT00355914. Pain Physician. 2007 May;10(3):425-40.
- Individual participant dataSharing planned: Undecided
Related trials for Pain, Postoperative
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rustom Manecksha contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Levobupivacaine and Dexamethasone Sodium Phosphate in people with Pain, Postoperative and Ureter Stone, run by The Adelaide and Meath Hospital, incorporating The National Children's Hospital at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Nikita Bhatt (00353860609430, nikitarb89@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain (time frame: at up to 7 days post op). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03296189, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2018.